|
🐜
|
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
14 auth.
J. O’Shaughnessy,
D. Miles,
S. Vukelja,
V. Moiseyenko,
J. Ayoub,
G. Cervantes,
P. Fumoleau,
Stephen E. Jones,
W. Lui,
L. Mauriac,
...
C. Twelves,
G. V. van Hazel,
S. Verma,
R. Leonard
|
10 |
2002 |
10
🐜
|
|
🐜
|
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
12 auth.
K. Blackwell,
H. Burstein,
A. Storniolo,
H. Rugo,
G. Sledge,
M. Koehler,
...
C. Ellis,
M. Casey,
S. Vukelja,
J. Bischoff,
J. Baselga,
J. O’Shaughnessy
|
9 |
2010 |
9
🐜
|
|
🐜
|
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
15 auth.
H. Burris,
H. Rugo,
S. Vukelja,
C. Vogel,
R. Borson,
S. Limentani,
E. Tan-chiu,
I. Krop,
R. Michaelson,
S. Girish,
...
L. Amler,
M. Zheng,
Y. Chu,
B. Klencke,
J. O’Shaughnessy
|
9 |
2011 |
9
🐜
|
|
🐜
|
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
20 auth.
Stephen N. Jones,
F. Holmes,
J. O’Shaughnessy,
J. Blum,
S. Vukelja,
K. McIntyre,
J. Pippen,
J. H. Bordelon,
R. Kirby,
J. Sandbach,
...
W. Hyman,
D. Richards,
R. Mennel,
K. Boehm,
W. Meyer,
L. Asmar,
D. Mackey,
Stefan Riedel,
H. Muss,
M. Savin
|
9 |
2009 |
9
🐜
|
|
🐜
|
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
12 auth.
K. Blackwell,
H. Burstein,
A. Storniolo,
H. Rugo,
G. Sledge,
G. Aktan,
...
C. Ellis,
A. Florance,
S. Vukelja,
J. Bischoff,
J. Baselga,
J. O’Shaughnessy
|
9 |
2012 |
9
🐜
|
|
🐜
|
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
13 auth.
F. Holmes,
J. O’Shaughnessy,
S. Vukelja,
Stephen E. Jones,
J. Shogan,
M. Savin,
J. Glaspy,
M. Moore,
L. Meza,
I. Wiznitzer,
...
T. Neumann,
L. Hill,
B. C. Liang
|
9 |
2002 |
9
🐜
|
|
🐜
|
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
20 auth.
Stephen E. Jones,
M. Savin,
F. Holmes,
J. O’Shaughnessy,
J. Blum,
S. Vukelja,
K. McIntyre,
J. Pippen,
J. H. Bordelon,
R. Kirby,
...
J. Sandbach,
W. Hyman,
P. Khandelwal,
A. Negron,
D. Richards,
S. Anthony,
R. Mennel,
K. Boehm,
W. Meyer,
L. Asmar
|
8 |
2006 |
8
🐜
|
|
🐜
|
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
22 auth.
J. Blum,
P. Flynn,
G. Yothers,
L. Asmar,
C. Geyer,
S. Jacobs,
N. Robert,
J. Hopkins,
J. O’Shaughnessy,
C. Dang,
...
H. Gómez,
L. Fehrenbacher,
S. Vukelja,
A. Lyss,
D. Paul,
A. Brufsky,
Jong-Hyeon Jeong,
L. Colangelo,
S. Swain,
E. Mamounas,
Stephen E. Jones,
N. Wolmark
|
7 |
2017 |
7
🐜
|
|
🐜
|
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
19 auth.
Y. Gong,
Kai Yan,
F. Lin,
K. Anderson,
C. Sotiriou,
F. André,
F. Holmes,
V. Valero,
D. Booser,
J. Pippen,
...
S. Vukelja,
H. Gómez,
J. Mejia,
Luis J Barajas,
K. Hess,
N. Sneige,
G. Hortobagyi,
L. Pusztai,
W. Symmans
|
7 |
2007 |
7
🐜
|
|
🦁
|
Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer
S. Vukelja,
J. O’Shaughnessy,
D. Weckstein
|
7 |
2007 |
7
🦁
|
|
🐬
|
Angiofollicular lymph node hyperplasia (Castleman's disease).
Matthew J. McCarty,
S. Vukelja,
P. Banks,
R. Weiss
|
7 |
1995 |
7
🐬
|
|
🐜
|
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
19 auth.
Stephen E. Jones,
R. Collea,
D. Paul,
S. Sedlacek,
A. Favret,
I. Gore,
D. Lindquist,
F. Holmes,
M. Allison,
B. Brooks,
...
Raul M Portillo,
S. Vukelja,
Michael S. Steinberg,
C. Stokoe,
M. Crockett,
Yunfei Wang,
L. Asmar,
N. Robert,
J. O’Shaughnessy
|
7 |
2013 |
7
🐜
|
